CAMBRIDGE, UK and SAN DIEGO, USA – April 20, 2017 – Congenica and Edico Genome today announced the companies have partnered to offer their complementary platform technologies as an all-in-one, genome data analysis solution that accelerates clinical labs’ and hospitals’ progression from DNA sequencing to diagnosis for inherited diseases which otherwise takes months or years.... Read more
Company Holds Largest IP Portfolio Encompassing Processor-Based Analysis of Next-Generation Sequencing Data SAN DIEGO, March 20, 2017 – Edico Genome, creator of the world’s first processor designed to analyze next-generation sequencing data, today announced the United States Patent and Trademark Office has issued an additional five, foundational patents surrounding the DRAGEN™ platform for analysis and storage... Read more
Thermo Fisher Scientific Inc. today announced that results from the multi-center Procalcitonin MOnitoring SEpsis (MOSES) Study have been published in the May 2017 print issue of Critical Care Medicine. Researchers from the study, titled “Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study,” investigated the use of... Read more
Thermo Fisher Scientific has signed an agreement with the Institute of Medical Genetics and Pathology at University Hospital Basel, Switzerland, to establish the leading institution as the first partner in the Next Generation Sequencing Companion Dx Center of Excellence Program, a new initiative designed to develop and refine Thermo Fisher’s NGS-based research assays from its... Read more
AUSTIN, Texas, April 20, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Bank of America Merrill Lynch 2017 Health Care Conference on Tuesday, May 16 at 1:40pm PT in Las Vegas. The investor presentation will be webcast live and may be accessed at Luminex Corporation’s website at http://www.luminexcorp.com. Simply log... Read more